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Abbreviations: 
ECV = elective cardioversion; AF = atrial fibrillation; INR = international normalized ratio; 
TIA = transient ischaemic attack; CHA2DS2-VASc = congestive heart failure, hypertension, 
age ≥ 75 years (doubled), diabetes mellitus, prior stroke, transient ischaemic attack or 
thromboembolism (doubled), vascular disease, age 65 to 74 years and sex category 
(female, unless <65 years and no other risk factors); SD = standard deviation; ICD-10 = 
international classification of diseases; TTR = time in therapeutic range; PINRR = 
percentage of INR measurements in therapeutic range; ECG = electrocardiogram; J = Joule; 
ISTH = International Society on Thrombosis and Haemostasis; IQR = inter-quartile range; 
NOAC = non-Vitamin K antagonist oral anticoagulant 
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ABSTRACT 
Background:  Elective cardioversion (ECV) for atrial fibrillation (AF) is associated with a 
relatively low risk of thromboembolic complications. However, the optimal intensity of 
anticoagulation for ECV is unknown. We sought to assess the risk of thromboembolism in 
low (INR 2.0-2.4) vs. high (INR≥2.5) therapeutic range in a large retrospective cohort study. 
Methods: This multi-centre “real world” study included 1424 ECVs in 1021 patients. The 
primary outcome was a stroke or a transient ischaemic attack (TIA) or a systemic embolus 
during the 30-day follow-up after ECV. 
Results: Altogether 4 (0.3%) strokes, 2 (0.1%) TIAs and 2 (0.1%) bleeds were detected 
during the 30-day follow-up after ECV. No systemic emboli were detected. There were 2 
deaths (0.1%), one associated with a stroke. Median time to stroke/TIA was 4 (IQR 9.5) 
days and the median CHA2DS2-VASc-score was 2 (IQR 1.25) among patients with 
thromboembolic events. Mean INR at ECV was 2.7 (SD 0.54) in the study cohort. Patients 
with INR 2.0-2.4 at ECV had more thromboembolic events compared with patients with 
INR≥2.5 (5/529 (0.9%) vs. 1/895 (0.1%), p=0.03). Comprehensive postprocedural INR data 
was available for 733 (71.8%) patients and 1007 cardioversions. At least one 
subtherapeutic (<2.0) INR value was detected within 21 days after 230 (22.8%) ECVs and 
this drop in INR level was associated with a higher risk for thromboembolic events 
compared with continuous therapeutic post-cardioversion anticoagulation (1.7% vs 0.3%, 
p=0.03). 
Conclusions: Our results suggest that the intensity of periprocedural anticoagulation is 
associated with the risk of thromboembolic events after ECV. 
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INTRODUCTION 
Annual stroke rate in atrial fibrillation (AF) without anticoagulation is approximately 3% [1], 
but the risk can be reduced close to 1% with adequate anticoagulation [2]. Elective 
cardioversion (ECV) for >48h AF increases the risk of stroke substantially and the reported 
rates of thromboembolic events after ECV have varied between 3-7% in non-anticoagulated 
patients [3,4]. In spite of the increased post-cardioversion risk, the target INR (2.0-3.0) for 
ECV has been similar to the general anticoagulation recommendations in the long-term 
management of AF, and is based on consensus of observations made in observational 
studies investigating anticoagulation for stroke prevention in AF [5,6]. Current guidelines 
recommend a minimum of 3 weeks of therapeutic anticoagulation prior to ECV and 4 weeks 
after the procedure with frequent INR controls for warfarin [5]. However, little is known how 
periprocedural INR levels predict thromboembolic events.  
In this study, we sought to evaluate whether the intensity of periprocedural anticoagulation 
with vitamin K antagonists in adequately anticoagulated patients predicts thromboembolic 
events after ECV of AF in contemporary clinical practice. Our hypothesis was that a more 
intense periprocedural anticoagulation is associated with a lower incidence of 
thromboembolic events. 
 
METHODS 
The FinCV2 study ([http://]www.ClinicalTrials.gov, identifier NCT02850679) is part of an 
ongoing study program exploring thrombotic and bleeding complications of AF in Finland [7-
11]. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5 
 
 
The current study is a prespecified report from FinCV2 study. Data was collected from 
patient registries in Turku University Hospital and two regional hospitals from a time period 
of 2003 – 2014 and in Kuopio University Hospital from a period of 2013 – 2015. Firstly, 
admission records and databases were used to review all patients above 18 years of age with 
>48h AF who underwent ECV in the participating hospitals during the study period (ICD-10 
code I48 for AF and TFP20 Nordic Classification of Surgical Procedures code for 
cardioversion). In addition, only patients living in the hospital catchment area were included 
in order to get the comprehensive follow-up data after the cardioversion. Each of the 
hospitals is the only referral hospital responsible for the acute care of patients presenting 
with cardiac or stroke events in their catchment areas.  
Preliminary screening resulted in 2373 patients. Thus, the initial study cohort of 1271 
patients with 1894 ECVs performed for AF with a duration >48h was then manually 
identified. After the initial screening, all patient files were reviewed individually. 
Comprehensive data on duration of AF, relevant clinical characteristics and, medications, 
together with cardioversion and periprocedural anticoagulation details were collected from 
the patient records. The present study focused on patients with adequate warfarin 
anticoagulation (INR maintained within therapeutic range (2.0-3.0) consistently for ≥3 
weeks, tested at least once a week) prior to the ECV. 
To further evaluate the efficacy of warfarin management, the INR data for 30 days before 
and 30 days after ECV for patients treated in Turku University Hospital and 2 regional 
hospitals were explored from the laboratory database provided by Turku University Hospital 
laboratory service (TYKSLAB). The additional INR data was available for 733 patients and 
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1007 ECVs. TTRs (time in therapeutic range) and PINRRs (percentage of INR measurements 
in therapeutic range) were determined for the 30 days before and after ECV. 
ECVs were performed according to the contemporary guidelines under general anaesthesia. 
During and after the procedure, ECG, blood pressure and oxygen saturation were monitored. 
Paddles or pads were positioned in antero-posterior or antero-lateral configuration. The 
energy ranged from 70 to 200J with biphasic defibrillator devices and from 70 to 360J with 
monophasic devices. A 12-lead ECG was controlled before and after the procedure. ECVs 
were performed by biphasic defibrillator after 2004.  
 
Outcomes 
For the present analysis, patients were divided into two groups according to the INR at the 
time of ECV; those with low (2.0 – 2.4) INR and those with high (≥2.5) therapeutic INR. All 
patients were followed up for 30 days after the cardioversion and thromboembolic 
complications, systemic embolic events, bleeding events (categorized according to the ISTH 
criteria [12]) and mortality were recorded. The primary outcome was a fatal or non-fatal 
stroke or a transient ischaemic attack (TIA) adjudicated by the treating neurologist with 
appropriate imaging or systemic embolus confirmed by the attending vascular surgeon and 
by imaging. 
 
Ethics 
The study received approval of the Medical Ethics Committee of the Hospital District of 
Southwest Finland and the ethics committee of the National Institute for Health and 
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Welfare. The study conforms to the Declaration of Helsinki. Informed consent was not 
required due to the retrospective registry set-up of the study. 
 
Statistics 
The unpaired t-test or Mann-Whitney test was used to compare continuous variables and 
Pearson x2 or Fisher’s exact test to compare categorical variables in the study subgroups, as 
appropriate. Normality in continuous covariates was tested with Kolmogorov-Smirnov and 
Shapiro-Wilk tests. Normally distributed continuous variables were reported as mean ± 
standard deviation whereas skewed continuous variables were denoted as median [inter-
quartile ranger (IQR)]. Categorical variables were reported with absolute and relative 
(percentage) frequencies. Baseline variables correlating at p<0.10 significance level with the 
dependent variable in univariate models were entered in multivariate logistic regression 
analysis. All tests were two-sided and significance was set at p=0.05. IBM SPSS Statistics 
software version 22.0 and SAS 9.4 statistical software (SAS Institute Inc, Cary, North 
Carolina) were used to perform all analyses as appropriate. 
 
RESULTS 
After patients with inadequate preprocedural warfarin treatment or partially unavailable INR 
data as well as patients receiving direct oral anticoagulants or low molecular weight heparin 
at the time of ECV were excluded, the final study population comprised of 1021 patients and 
1424 ECVs (Figure 1). 
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Altogether low (2.0-2.4) therapeutic INR and high (≥2.5) therapeutic INR was measured at 
the time of 529 and 895 ECVs, respectively. Mean age of study patients was 64 (SD 9.8) and 
419 (29.4%) patients were female. The median number of ECVs was 1 per patient with a 
range of 1-8 and the median time between two procedures was 136 (IQR 504) days. The 
mean INR at ECV was 2.7 (SD 0.54) and the mean CHA2DS2-VASc-score was 2.0 (SD 1.6). 
Transoesophageal echocardiography was performed before 31 (2.2%) ECVs to exclude atrial 
thrombus. ECV was successful in 1205 (84.6%) cases. 
 
Outcomes  
At 30-day follow-up after ECV, 4 (0.3%) strokes and 2 (0.1%) TIAs were detected (Table 1). 
There were no systemic emboli, but one patient suffered a pulmonary embolism one day 
after a successful ECV. Additionally, one (0.1%) major bleed and one (0.1%) clinically relevant 
non-major bleed (1 traumatic subdural haemorrhage and 1 bleeding after dental procedure 
causing sinus perforation and requiring nasal tamponade) occurred during the follow-up. No 
spontaneous bleeds were detected. Two patients (0.1%) died during follow-up (1 associated 
with stroke and 1 with congestive heart failure, renal failure and infection). One death and 
one major bleed were detected in patients with INR 2.0-2.4 and INR≥2.5 at ECV, respectively. 
Median time to a stroke/TIA was 4 (IQR 9.5) days after ECV. The median CHA2DS2-VASc-score 
was 2 (IQR 1.25) in patients suffering thromboembolic events. All thromboembolic events 
occurred after successful ECVs. 
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Intensity of anticoagulation and risk of thromboembolism 
The risk for a thromboembolic event was higher in the group of patients with low (2.0-2.4) 
therapeutic INR at ECV than in those with INR≥2.5 at ECV (5/529 (0.9%) vs. 1/895 (0.1%), 
p=0.03) (Figure 2). Baseline characteristics of these patient groups were similar, but patients 
without prior AF episodes had more often (p<0.05) low therapeutic INR values at ECV (Table 
2.) The results did not change when only the first ECV of each patient was analysed (5/389 
(1.3%) vs. 0/632 (0%), p=0.01). In the 733 patients with additional INR data, mean TTR (2.0-
3.0) was 76% during 30 days prior to ECV. The relatively low TTR value was explained by high 
(>3.0) INR values measured during the preprocedural time period. 
During the 21 days after ECV, a drop in INR to subtherapeutic (<2.0) level was detected in 
230 (22.8%) cardioversions and the risk for a thromboembolic event was significantly 
higher in these patients than in those with all INR measurements ≥2.0 after ECV (1.7% vs 
0.3%, p=0.03) (Figure 2). Correspondingly, the mean TTRs and PINRRs were lower in 
patients with a subtherapeutic INR during the 30 days after ECV when compared to those 
with all INRs ≥2.0 (55% vs 79%, p<0.01 and 45% vs 73%, p. <0.01, respectively). In a 
multivariate analysis, low (2.0-2.4) INR at ECV (OR 1.93, CI95% 1.38-2.69; p<0.01) predicted 
a drop in INR to subtherapeutic (<2.0) level within 21 days after ECV. 
 
DISCUSSION 
In this large retrospective multi-center study patients with low (2.0-2.4) therapeutic INR at 
ECV or those with subtherapeutic (<2.0) INR measurements within 21 days after ECV had an 
increased risk for thromboembolic events (Figure 2). Importantly, every fourth patient 
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experienced a drop of INR to subtherapeutic level after ECV, and low periprocedural INR 
levels appeared to predict the drop in INR after ECV.   
Modern oral anticoagulation has reduced AF-related stroke risk to 0.1-0.2%/month in the 
long-term treatment [2]. The risk of thromboembolic complications after ECV performed 
during therapeutic oral anticoagulation has ranged from 0.3% to 0.9% in previous trials [13-
15]. This means that patients undergoing ECV are exposed to a 1.5-4.5 -fold higher risk for 
stroke during the post-cardioversion month compared to patients without a cardioversion 
and there is a clinical need to reduce ECV related strokes. The magnitude of the problem is 
illustrated by a recent finding that 6.4% of all strokes associated with paroxysmal or 
persistent AF are preceded by a cardioversion [10]. In line with this reasoning, inadequate 
pericardioversion anticoagulation may have contributed to the poor outcome in the rhythm 
control arm of the AFFIRM study [16]. 
Thrombus formation in the left atrial appendage is responsible for the majority of 
thromboembolic events after cardioversion. In spite of the solid theoretical background, 
several clinical trials have concluded that performing transoesophageal echocardiography to 
exclude thrombus formation prior to ECV does not reduce the rate of stroke compared to 
conventional anticoagulation regime [13,15]. Early cardioversion may, however, be 
advantageous in this respect, since the risk for stroke has shown to be low (0.1% per month) 
in patients undergoing cardioversion within 48 hours after the onset of AF during long-term 
oral anticoagulation [11]. This finding is probably explained by less atrial stunning and 
thrombus formation after the conversion of shorter episode of AF to sinus rhythm. 
One important finding of our study was the high incidence of subtherapeutic INR values 
during the most vulnerable period of atrial stunning after the cardioversion. This finding may 
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reflect the more floppy general attitude on anticoagulation after achieving the sinus rhythm 
and therefore assuming a lower risk of thromboembolism. The use of non-Vitamin K 
antagonist oral anticoagulants (NOACs) should help to ensure stable therapeutic 
periprocedural anticoagulation in patients with good drug compliance. The conventional 
dosing of NOACs has, however, provided no significant advantage over vitamin K antagonist 
anticoagulants in this setting, although numerically the event rates have been slightly lower 
and less delays to cardioversion have been reported [14,15,17].  
The target pericardioversion anticoagulation level is based on consensus opinion and does 
not differ from the general anticoagulation recommendations in the long-term management 
of AF in spite of the higher temporary risk of thromboembolic complications after successful 
cardioversion. Our findings support the view that the higher intensity of periprocedural 
anticoagulation - even within the current therapeutic range - may reduce the risk of 
thromboembolic complications. These observations are in line with an earlier study where 
no embolic events were detected after 779 ECVs with periprocedural INR ≥ 2.5 whereas 7 
(0.9%) embolic events occurred after 754 ECVs with INR <2.5 [18]. Similarly, the risk of 
thromboembolism was numerically lower (0.3% vs 0.8%) during chronic anticoagulation with 
high dabigatran dose (150mg twice daily) than with the lower dose (110mg twice daily) [19].  
In the light of present and earlier findings it seems unlikely that a short period of more 
intensive anticoagulation causes redundant rise in the risk for bleeds during the peri- and 
post-cardioversion treatment [6], since the monthly rates for bleeds have been similar (0.1-
0.3% per month) in trials investigating anticoagulation of non-valvular AF [2] and venous 
thromboembolism with higher doses of NOACs [20,21]. Nevertheless, the efficacy and safety 
of the more intensive periprocedural anticoagulation of ECV in AF needs to be assessed in a 
prospective randomized trial. 
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This study has all the limitations of a retrospective study. The total number of embolic 
events is low for definite conclusions and an interruption of anticoagulation treatment 
occurred in two patients with thromboembolic events. Furthermore, comprehensive 
periprocedural INR data was unavailable in all patients reducing the sample size. Events 
were not independently adjudicated, however, all events were diagnosed by the treating 
neurologist with appropriate imaging or systemic embolus confirmed by the attending 
vascular surgeon and by imaging. Moreover, all patients were from the catchment area of 
the participating hospitals and thus all thromboembolic events are treated in the same 
hospital. Despite the limitations, we feel that this data can guide future research and 
treatment decisions in patients undergoing ECV. 
 
CONCLUSIONS 
Our results provide indirect evidence that the increased risk of thromboembolic events 
related to ECV might be reduced by more aggressive anticoagulation and careful follow-up 
during the periprocedural period. However, further research is needed to definitely assess 
the efficacy and safety outcomes of the hypothesis. Our study demonstrates the importance 
of rigorous and good quality INR control after a successful ECV in stroke prevention. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
13 
 
 
Acknowledgements 
This work was supported by the Finnish Foundation for Cardiovascular Research, the Finnish 
Medical Foundation, and the Turku University Hospital (TYKS) Foundation.    
 
Disclosures 
All authors have approved submission of the manuscript, and the manuscript has not been 
published and is not being considered for publication elsewhere. The authors do not have 
any conflicts of interest in connection with the submitted article. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
14 
 
 
Reference list: 
 
1 Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL: Stroke 
with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke 
Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 35 (2000) 183-187. 
2 Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo 
AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip 
LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T: Edoxaban versus 
warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013) 2093-2104. 
3 Weinberg DM, Mancini J: Anticoagulation for cardioversion of atrial fibrillation. 
Am J Cardiol 63 (1989) 745-746. 
4 Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG: Role of prophylactic 
anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial 
flutter. J Am Coll Cardiol 19 (1992) 851-855. 
5 Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, 
Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, 
Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, 
Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, 
Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, 
Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor 
CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K: 2016 ESC Guidelines 
for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 
37 (2016) 2893-2962. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
15 
 
 
6 van Latum JC KP, van Gijn J, Kappelle LJ, Algra A.: Optimal oral anticoagulant 
therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The 
European Atrial Fibrillation Trial Study Group. N Engl J Med 333 (1995) 5-10. 
7 Hellman T, Kiviniemi T, Vasankari T, Nuotio I, Biancari F, Bah A, Hartikainen J, 
Mäkäräinen M, Airaksinen KE: Prediction of ineffective elective cardioversion of atrial 
fibrillation: a retrospective multi-center patient cohort study. BMC Cardiovasc Disord 17 
(2017) 33. DOI: 10.1186/s12872-017-0470-0 
8 Airaksinen KE, Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, 
Hartikainen JE: Thromboembolic complications after cardioversion of acute atrial fibrillation: 
the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 62 (2013) 1187-1192. 
9 Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Vasankari T, Hartikainen JE, 
Airaksinen KE: Arrhythmic complications after electrical cardioversion of acute atrial 
fibrillation: the FinCV study. Europace 15 (2013) 1432-1435. 
10 Palomäki A, Mustonen P, Hartikainen JE, Nuotio I, Kiviniemi T, Ylitalo A, 
Hartikainen P, Lehtola H, Luite R, Airaksinen KE: Strokes after cardioversion of atrial 
fibrillation--The FibStroke study. Int J Cardiol 203 (2016) 269-273. 
11 Grönberg T, Hartikainen JE, Nuotio I, Biancari F, Ylitalo A, Airaksinen KE: 
Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute 
Atrial Fibrillation (from the FinCV Study). Am J Cardiol 117 (2016) 1294-1298. 
12 Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, 
Lillicrap D, ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working 
Group.: ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for 
a new bleeding score for inherited bleeding disorders. J Thromb Haemost 8 (2010) 2063-
2065. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
16 
 
 
13 Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, 
Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF, Investigators ACUTE: 
Use of transesophageal echocardiography to guide cardioversion in patients with atrial 
fibrillation. N Engl J Med 344 (2001) 1411-1420. 
14 Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, 
Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van 
Eickels M, Hohnloser SH, Investigators X-VerT: Rivaroxaban vs. vitamin K antagonists for 
cardioversion in atrial fibrillation. Eur Heart J 35 (2014) 3346-3355. 
15 Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri 
MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, 
Batushkin V, de Groot JR, Lip GY, investigators E-A: Edoxaban versus enoxaparin-warfarin in 
patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-
label, phase 3b trial. Lancet 388 (2016) 1995-2003. 
16 Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen 
JC, Greene HL, Mickel MC, Dalquist JE, Corley SD, Investigators AFFIRM: A comparison of rate 
control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-
1833. 
17 Caldeira D, Costa J, Ferreira JJ, Lip GY, Pinto FJ: Non-vitamin K antagonist oral 
anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and 
meta-analysis. Clin Res Cardiol 104 (2015) 582-590. 
18 Gallagher MM, Hennessy BJ, Edvardsson N, Hart CM, Shannon MS, Obel OA, Al-
Saady NM, Camm AJ: Embolic complications of direct current cardioversion of atrial 
arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J 
Am Coll Cardiol 40 (2002) 926-933. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
17 
 
 
19 Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker 
G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ: Dabigatran versus 
warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. 
Circulation 123 (2011) 131-136. 
20 Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, 
Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, 
Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A, Investigators EINSTEIN-PE: Oral 
rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366 
(2012) 1287-1297. 
21 Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra 
D, Schnee J, Goldhaber SZ, Group RE-COVER: Dabigatran versus warfarin in the treatment of 
acute venous thromboembolism. N Engl J Med 361 (2009) 2342-2352. 
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
18 
 
 
Table 1. Characteristics of the thromboembolic events after ECV 
 Event Age/Sex Time 
after ECV 
(days) 
CHA2DS2-
VASc -score 
TEE INR 
(ECV) 
INR 
(Event) 
Other 
Pt 1 Stroke 53M 12 1 No 2.4 1.4 Traumatic subdural 
haemorrhage before stroke 
Pt 2 Stroke 65M 5 2 No 2.1 1.9 warfarin pause due to 
cataract surgery 
Pt 3 Stroke 73M 11 2 No 2.2 4.4 - 
Pt 4 Stroke 75M 3 2 No 2.8 2.4 - 
Pt 5 TIA 70M 1 1 No 2.2 1.9 - 
Pt 6 TIA 53F 2 0 No 2.2 2.2 -  
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ECV= elective cardioversion; CHA2DS2-VASc = congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke, 
transient ischaemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years and sex category (female, unless <65 years and no 
other risk factors); TEE = transoesophageal echocardiography; INR = international normalized ratio; Pt = patient; M = male; F = female; TIA = 
transient ischaemic attack
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Table 2. Baseline characteristics of patients with low (2.0-2.4) therapeutic INR vs high 
(≥2.5) therapeutic INR at ECV. 
 INR 2.0-2.4     
(N=529) 
INR≥2.5    
(N=895) 
p 
Age>75 years 88 (16.6) 134 (15.0) 0.60 
Female 150 (28.4) 269 (30.1) 0.51 
First AF episode 279 (52.7) 419 (46.8) 0.03 
Prior cardioversion 211 (39.9) 404 (45.1) 0.10 
CHA2DS2-VASc-score ≥2 304 (57.5) 529 (59.1) 0.58 
Duration of the index AF 
episode <90 days a 
202 (65.4) 341 (66.7) 0.51 
Duration of AF disease ≤1year 262 (57.7) 404 (52.6) 0.09 
History of heart failure 67 (12.7) 127 (14.2) 0.47 
Hypertension 300 (56.7) 473 (52.8) 0.17 
History of kidney disease 30 (5.7) 54 (6.0) 0.82 
Diabetes 73 (13.8) 142 (15.9) 0.32 
Prior stroke/TIA 38 (7.2) 52 (5.8) 0.31 
Coronary artery disease 74 (14.0) 144 (16.1) 0.32 
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Medication at discharge    
    Aspirin  14 (2.6) 16 (1.8) 0.41 
 
a exact duration not available in 604 (42.4%) cardioversions. 
 
Values in parentheses are %, INR = international normalized ratio; AF = atrial fibrillation; 
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes 
mellitus, prior stroke, transient ischaemic attack or thromboembolism (doubled), vascular 
disease, age 65 to 74 years and sex category (female, unless <65 years and no other risk 
factors); TIA = transient ischaemic attack 
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Figure legends 
 
Figure 1. Flow chart illustrating patient selection in the study. 
AF = atrial fibrillation; ECV = elective cardioversion 
 
 
Figure 2. Incidence of thromboembolic events in patients with high (≥2.5) therapeutic INRs 
(full color) compared to those with low (2.0-2.4) therapeutic INRs (no color) at elective 
cardioversion (ECV) (Panel A), and in patients with therapeutic (≥2.0) vs. subtherapeutic 
(<2.0) INRs within 21 days after ECV (Panel B).  
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Fig. 2
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Highlights: 
 Risk of thromboembolic events in cohort of AF patients undergoing ECV was 
explored. 
 The incidence of thromboembolic events was 0.4%. 
 Patients with INR 2.0-2.4 at ECV had higher risk than those with INR≥2.5. 
 A drop in INR to low (<2.0) levels was detected after 22.8% cardioversions. 
 The INR drop was also associated with an increased risk for a thromboembolic event. 
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